Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics.
James T TophamJoanna M KarasinskaMichael Kuan-Ching LeeVeronika CsizmokLaura M WilliamsonGun Ho JangRobert E DenrocheErica S TsangSteve E KallogerHui-Li WongGrainne M O'KaneRichard A MooreAndrew J MungallFaiyaz NottaJonathan M LoreeJulie M WilsonOliver F BathePatricia A TangRachel GoodwinJennifer J KnoxSteven GallingerJanessa LaskinMarco A MarraSteven J M JonesDaniel J RenoufDavid F SchaefferPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Nearly 1 in 6 patients with PDAC have tumors that fail to reliably fall into the classical or basal-like PDAC subtype categories, based on two regression tools aimed toward clinical practice. Rather, these patient tumors show intermediate prognostic and molecular traits. We propose close consideration of the non-binary nature of PDAC subtypes for future incorporation of subtyping into clinical practice.